An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild-type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferoninducible MxCre resulted in expression of JAK2-V617F approximately equal to wildtype Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild-type JAK2 is critical for the phenotypic manifestation.
IntroductionAn acquired somatic mutation in the JAK2 gene resulting in a valine to phenylalanine substitution at position 617 (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). [1][2][3][4] This discovery suggested that the presence of the JAK2-V617F mutation could represent the primary causative lesion in MPD. While the JAK2-V617F mutation is found in approximately 95% of patients with polycythemia vera (PV), it is also detectable in about 50% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET). 2,5 It remains unclear how the identical JAK2-V617F mutation can cause 3 distinct clinical entities. In patients with PV and PMF, but only rarely in ET, the JAK2-V617F mutation progresses from the heterozygous state to homozygosity through mitotic recombination of the distal part of chromosome 9p. 4,6 Retroviral transduction of mouse bone marrow cells followed by transplantation into lethally irradiated mice demonstrated that the expression of Jak2-V617F is sufficient to induce a phenotype resembling PV. 1,7-10 These mice showed massive increase in hematocrit and hemoglobin concentration and a variable degree of neutrophilia. In contrast to patients with PV, the platelet numbers in these mice remained normal or were even decreased. After several months some of the mice also developed myelofibrosis. The phenotype was not affected when bone marrow from donor mice deficient for the Src family kinases Lyn, Hck and Fgr were used, but was dependent on the presence of Stat5. 10,11 To establish a mouse model for MPD we generated bacterial artificial chromosome (BAC) transgenic mice that express the human JAK2-V617F driven by the JAK2 promoter. A constitutiv...
BackgroundThe tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3 + regulatory T-cells (Treg) in lymphomas.
Experimental autoimmune myocarditis (EAM) appears after infectious heart disease, the most common cause of dilated cardiomyopathy in humans. Here we report that mice lacking T-bet, a T-box transcription factor required for T helper (Th)1 cell differentiation and interferon (IFN)-γ production, develop severe autoimmune heart disease compared to T-bet
−/− control mice. Experiments in T-bet
−/−
IL-4−/− and T-bet
−/− IL-4Rα−/− mice, as well as transfer of heart-specific Th1 and Th2 cell lines, showed that autoimmune heart disease develops independently of Th1 or Th2 polarization. Analysis of T-bet
−/−
IL-12Rβ1−/− and T-bet
−/− IL-12p35−/− mice then identified interleukin (IL)-23 as critical for EAM pathogenesis. In addition, T-bet
−/− mice showed a marked increase in production of the IL-23–dependent cytokine IL-17 by heart-infiltrating lymphocytes, and in vivo IL-17 depletion markedly reduced EAM severity in T-bet
−/− mice. Heart-infiltrating T-bet
−/− CD8+ but not CD8− T cells secrete IFN-γ, which inhibits IL-17 production and protects against severe EAM. In contrast, T-bet
−/− CD8+ lymphocytes completely lost their capacity to release IFN-γ within the heart. Collectively, these data show that severe IL-17–mediated EAM can develop in the absence of T-bet, and that T-bet can regulate autoimmunity via the control of nonspecific CD8+ T cell bystander functions in the inflamed target organ.
Data availability statement. All data generated are included in the published article and in the Supplementary Information. Gene expression data that support the findings of this study have been deposited in the Gene Expression Omnibus under accession numbers GSE127200 and 127959. All data are also available from the authors on reasonable request.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.